AIM VACCINE CO., LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 8.03 HKD | 0.00% |
|
-2.31% | +2.29% |
| Mar. 28 | Aim Vaccine Submits Pre-Applications for Clinical Trials for Two Vaccines; Shares Up 3% | MT |
| Mar. 28 | Aim Vaccine's Loss Quadruples in 2023 as Revenue Slips 6%; Shares Up 3% | MT |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- The company is in debt and has limited leeway for investment
Ratings chart - Surperformance
Sector: Pharmaceuticals
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| +2.29% | 1.25B | - | ||
| -2.32% | 90.45B | A- | ||
| +3.68% | 41.45B | A- | ||
| -10.90% | 33.57B | B- | ||
| +58.05% | 25.73B | A | ||
| -19.56% | 14.73B | C | ||
| -9.06% | 12.82B | B- | ||
| -11.34% | 11.7B | D+ | ||
| -43.53% | 11.44B | B | ||
| +3.75% | 8.79B | B+ |
Investor Rating
Trading Rating
-
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
-
Finances
Valuation
P/E ratio
-
EV / Sales
Price to Book
Price to Free Cash Flow
-
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
-
4 months EPS revision
-
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
-
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- 6660 Stock
- Ratings AIM Vaccine Co., Ltd.
